Lexeo Therapeutics raised $100m to fund its gene research projects focused on cardiovascular and neurological diseases after reducing the price of its IPO. The New York-based firm’s focus ranges from rare diseases to common conditions with a genetically defined subset. Lexeo’s most advanced projects involve Friedreich’s ataxia, a rare neuromuscular disorder, and Alzheimer’s disease. The funding will also support two clinical-stage programs and others in its development pipeline.
Jennifer Williams has been named the new Vice President of Information Security at HOOPP. She brings a wealth of experience and expertise to the role,